Table 5.
Incidence of long-term kidney outcomes according to initial randomization to fenofibrate versus placebo (in addition to statin therapy), stratified by sex
| Outcomea | Women | Men | White Race | Nonwhite Race | ||||
|---|---|---|---|---|---|---|---|---|
| n=1634 (821 Fibrate, 813 Placebo) | n=3721 (1864 Fibrate, 1857 Placebo | n=3676 (1858 Fibrate, 1818 Placebo) | n=1679 (827 Fibrate, 852 Placebo) | |||||
| Event Number | HR/SHR (95% CI) | Event Number | HR/SHR (95% CI) | Event Number | HR/SHR (95% CI) | Event Number | HR/SHR (95% CI) | |
| Composite kidney outcome | 284 Feno | 1.32 (1.11 to 1.57)c | 703 Feno | 1.10 (0.99 to 1.22) | 680 Feno | 1.08 (0.97 to 1.20) | 307 Feno | 1.36 (1.15 to 1.61)c |
| 232 Plac | 647 Plac | 629 Plac | 250 Plac | |||||
| Macroalbuminuriab | 88 Feno | 1.51 (1.07 to 2.14)c | 212 Feno | 1.01 (0.82 to 1.24) | — | — | ||
| 57 Plac | 190 Plac | |||||||
| Doubling of creatinine | — | — | 220 Feno | 1.82 (1.46 to 2.28)c | 111 Feno | 2.08 (1.51 to 2.86)c | ||
| 121 Plac | 63 Plac | |||||||
| Dialysis | 31 Feno | 1.03 (0.61 to 1.75) | 67 Feno | 1.12 (0.76 to 1.66) | — | — | ||
| 31 Plac | 69 Plac | |||||||
| All-cause mortality | — | — | 379 Feno 416 Plac | 0.88 (0.76, 1.01) | 152 Feno | 1.26 (1.0, 1.60) | ||
| 128 Plac | ||||||||
HR, hazard ratio; SHR, subhazard ratio; 95% CI, 95% confidence interval; Feno, fenofibrate; Plac, placebo; —, analysis not performed because interaction term was not significant.
a
HRs and 95% CIs are for fully adjusted multivariable analyses using contrast statements from models with participants from both subtrials.
b
Denominators for macroalbuminuria outcome among women: 709 fenofibrate, 713 placebo; among men: 1645 fenofibrate, 1603 placebo; among whites: 1646 fenofibrate, 1587 placebo; among nonwhites: 708 fenofibrate, 729 placebo.
c
Statistically significant results.